フローサイトメーター

世界のリサーチ分野のお客さまへ先端の検査装置のご案内です。

  • 神戸:078-992-6272
  • 東京:03-5434-8556

【受付時間09:00~17:35※土日休日を除く/その他休日はサイト上で告知

お問い合わせ

sysmex

フローサイトメーターsysmex

CyFlow CD79b FITC

品番 AD303625
抗体名 Anti-Hu CD79B FITC,CB3-1
包装単位 100 tests
濃度 -
容量 0.4 ml
関連製品
(アイソタイプコントロール)
Mouse IgG1 FITC (CD051682)
反応性|交差吸着 Human レーザー Blue
抗原 CD79b, IgB, B29 最大蛍光波長 518 nm
クローン CB3-1 最大励起波長 490 to 495 nm
ホスト Mouse 標識/Format FITC
アイソタイプ IgG1 研究分野 Immunophenotyping
クローナリティ monoclonal 用途

Flow cytometry

Anti-Hu CD79B FITC,CB3-1

特異性

The mouse monoclonal antibody CB3-1 recognizes an extracellular epitope of CD79b, a 38 kDa component of B cell receptor (BCR) complex.

抗原情報

CD79b (Ig β, B29) forms disulfide-linked heterodimer with CD79a (Ig α, MB1). They both are transmembrane proteins with extended cytoplasmic domains containing immunoreceptor tyrosine activation motives (ITAMs), and together with cell surface immunoglobulin they constitute B-cell antigen-specific receptor (BCR). CD79a and b are the first components of BCR that are expressed developmentally. They appear on pro-B cells in association with the endoplasmic reticulum chaperone calnexin. Subsequently, in pre-B cells, CD79 heterodimer is associated with λ5-VpreB surrogate immunoglobulin and later with antigen-specific surface immunoglobulins. CD79a/b complex interacts with Src-family tyrosine kinase Lyn, which phosphorylates its cytoplasmic ITAM motives to form docking sites for downstream signaling.

利用方法

The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 4 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.

保存方法

Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.

安定性情報

Do not use after expiration date stamped on vial label.

レファレンス

• D'Arena G, Cascavilla N, Musto P, Colella Bisogno R, Pistolese G, Carotenuto M: CD79b expression in B‑cell chronic lymphocytic leukemia. Haematologica. 2000·May; 85(5):556‑7. <·PMID:·10800181·>
• Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go MA, Jack A, Junutula JR, Koeppen H, Lau J, McBride J, Rawstron A, Shi X, Yu N, Yu SF, Yue P, Zheng B, Ebens A, Polson AG: Therapeutic potential of an anti‑CD79b antibody‑drug conjugate, anti‑CD79b‑vc‑MMAE, for the treatment of non‑Hodgkin lymphoma. Blood. 2009·Sep·24; 114(13):2721‑9. <·PMID:·19633198·>
• Garcia Vela J, Delgado I, Benito L, Monteserin M, Garcia Alonso L, Somolinos N, Andreu M, Oña F: CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection. Leukemia. 1999·Oct; 13(10):1501‑5. <·PMID:·10516749·>
• Matutes E: New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders. J·Clin·Pathol. 2002·Mar; 55(3):180‑3. <·PMID:·11896067·>
• Nakamura T, Kubagawa H, Cooper MD: Heterogeneity of immunoglobulin‑associated molecules on human B cells identified by monoclonal antibodies. Proc·Natl·Acad·Sci·USA. 1992·Sep·15; 89(18):8522‑6. <·PMID:·1382292·>
• Rassenti LZ, Kipps TJ: Expression of Ig‑beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy‑chain allelic exclusion. Blood. 2000·Apr·15; 95(8):2725‑7. <·PMID:·10753858·>
• Zheng B, Fuji RN, Elkins K, Yu SF, Fuh FK, Chuh J, Tan C, Hongo JA, Raab H, Kozak KR, Williams M, McDorman E, Eaton D, Ebens A, Polson AG: In vivo effects of targeting CD79b with antibodies and antibody‑drug conjugates. Mol·Cancer·Ther. 2009·Oct; 8(10):2937‑46. <·PMID:·19808977·>

Available Safety Data Sheets

CyFlow™ monoclonal antibodies SDS CA EN

Available Technical Data Sheets

CyFlow™ CD79b FITC (CB3-1) AD303625 TDS (US)